Breaking Finance News

Celgene Corporation (NASDAQ:CELG) target price raised to $127.00, reported today by Citigroup

Celgene Corporation (NASDAQ:CELG) had its target price raised to $127.00 by Citigroup in a report released Thursday September 29, 2016. The new target price indicates a possible upside of 0.23% based on the company's last stock close price.

Previously on 9/22/2016, Vetr Inc. reported about Celgene Corporation (NASDAQ:CELG) raised the target price from $0.00 to $122.94. At the time, this indicated a possible upside of 0.11%.

Yesterday Celgene Corporation (NASDAQ:CELG) traded -2.51% lower at $103.53. The company’s 50-day moving average is $109.05 and its 200-day moving average is $105.27. The last stock close price is down -2.00% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 2,752,220 shares of the stock were exchanged, down from an average trading volume of 4,170,760

See Chart Below

Celgene Corporation (NASDAQ:CELG)

Celgene Corporation has a 52 week low of $93.05 and a 52 week high of $128.39 with a P/E ratio of 43.61 The company’s market cap is currently $0.

In addition to Citigroup reporting its target price, a total of 22 firms have reported on the stock. The consensus target price is $136.82 with 10 firms rating the stock a strong buy, 10 firms rating the stock a buy, 4 firms rating the stock a hold, 1 firm rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Celgene Corporation (NASDAQ:CELG)

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company's primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company's clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *